tiprankstipranks
Analyst Profile
Followed by 32 other investors
.
Gil Blum

Gil Blum

Needham
Wall Street Analyst
Ranked #6,677 out of 8,047 Analysts on TipRanks (#17,856 out of 21,521 overall experts)

Success Rate

45%
74 out of 165 Profitable Transactions

Average Return

-2.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Gil Blum's ratings since 2022 and opened each position for the duration of 1 Year:
44.85% of your transactions would have been profitable with an average return of -2.3%

Stock Rating Distribution

214Ratings
92.52% Buy
7.48% Hold
0.00% Sell
Distribution of Gil Blum's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
CTI BioPharma Corp.
(CTIC)
Rating Type:Buy
Dates:Dec 01, 2021 - Jan 01, 1970
Gain:253.00%
The most profitable rating made by Gil Blum

Gil Blum's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Athenex
Hold
Assigned
0.00%
3
Genocea Biosciences
Buy
Reiterated
$6.00
(54445.45% Upside)
0%
-83.56%
5
Athersys
Hold
Assigned
0%
-67.42%
6
Mereo Biopharma Group Plc
Buy
Reiterated
$5.00
(270.37% Upside)
67%
+58.60%
8
Selecta Biosciences
Buy
Reiterated
$5.00
(103.25% Upside)
67%
+76.88%
7
Nurix Therapeutics
Buy
Reiterated
$32.00
(91.27% Upside)
33%
+0.38%
9
I-MAB
Buy
Reiterated
$72.00
(802.26% Upside)
0%
-55.79%
10
Bavarian Nordic AS
Buy
Reiterated
kr370.00
(9.00% Upside)
100%
+87.23%
10
Gamida Cell
Buy
Reiterated
$12.00
(298.67% Upside)
56%
+11.37%
9
G1 Therapeutics
Buy
Reiterated
$32.00
(148.64% Upside)
83%
+50.27%
6
List of latest recommendations made by Gil Blum. Click to expand and see Gil Blum's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More